Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...

Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

AbbVie (ABBV) and IGI Therapeutics SA have entered into an exclusive licensing agreement for the latter’s lead ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...

Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...

Glenmark shares hit record high after $2 billion AbbVie deal for cancer drug ISB 2001; analysts see it as a major biotech ...